(Reuters). The first quarter of Roche’s Swiss drugmaker rose 10%. It was driven by Ocrevus for multiple sclerosis and Hemlibra for haemophilia as well as drugs like Ocrevus. There is also strong demand in the U.S. for COVID-19 Antigen Tests.

The company announced Monday that quarterly sales increased to 16.44 billion Swiss Francs ($17.17 trillion), an increase of 14.93 billion Swiss Franks during the previous year. It was slightly more than what the market expected to be 16 billion francs.

Roche has also confirmed that it will be guiding 2022.

($1 = 0.9577 Swiss francs)